Who is sponsoring NCT05766735?

NCT05766735 is sponsored by Chiara Fabris, PhD.

What drugs are being tested in NCT05766735?

Interventions in NCT05766735: Routine Care + Glycemic Excursion Minimization (RC+GEM), Routine Care (RC).

What condition does NCT05766735 study?

NCT05766735 studies Type 2 Diabetes.

Is NCT05766735 still recruiting?

NCT05766735 is currently recruiting now. Last updated 9 April 2026.

Last reviewed 2026-04-09 · How we verify

NCT05766735: GEM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treating Early Type 2 Diabetes by Reducing Postprandial Glucose Excursions: A Paradigm Shift in Lifestyle Modification

Recruiting now NA Last updated 9 April 2026

What this trial tests

NA trial testing Routine Care + Glycemic Excursion Minimization (RC+GEM) in Type 2 Diabetes in 200 participants. Currently enrolling.

Timeline

8 August 2023

Primary endpoint
31 May 2027

31 May 2027

Quick facts

Lead sponsor	Chiara Fabris, PhD
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	200
Start date	8 August 2023
Primary completion	31 May 2027
Estimated completion	31 May 2027
Sites	2 locations across United States

Drugs / interventions tested

Routine Care + Glycemic Excursion Minimization (RC+GEM)
Routine Care (RC)

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →

Sponsor

Chiara Fabris, PhD

Who can join

Adults 30 to 80, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Randomized Control Trial (RCT) with 1:1 randomization of adults newly diagnosed with type 2 diabetes (T2D) to Routine Care (RC) and RC + Glycemic Excursion Minimization (RC+GEM); a program that provides RC in addition to continuous glucose monitors (CGM) within a structured, self-directed, and personalized lifestyle program called GEM. Our hypothesis is that RC+GEM will: 1) reduce hemoglobin A1c as much or more, 2) require less diabetes medication, 3) cost less, and 4) have more secondary benefits, (e.g. greater reduction in cardiovascular risk, weight, diabetes distress, depression symptoms), compared to RC alone.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05766735 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chiara Fabris, PhD
Last refreshed: 9 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05766735.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing